We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Dendreon has not demonstrated that its prostate cancer drug Provenge provides enough benefit over less expensive drugs to justify reimbursement, UK healthcare cost watchdog said this week. Read More
Shire will pay $5.2 billion to acquire rare disease manufacturer NPS Pharma, the latest acquisition aimed at boosting the Irish drugmaker’s rare disease portfolio. Read More
Daiichi Sankyo will pay the federal government $39 million to resolve allegations it used lavish dinners and other kickbacks to persuade physicians to prescribe more of the company’s drugs. Read More
A federal appeals court is expected to rule next month in a dispute over Actavis’s plan to pull an older formulation of its blockbuster Alzheimer’s drug Namenda from the market and replace it with a newer version. Read More
Mylan and Abbott have submitted proposed commitments to the European Commission’s competition oversight body to allay anti-competitive concerns over a proposed merger that would reincorporate Mylan in the Netherlands. Read More
Drug sponsors are expected to expand their investments in developing new cancer therapies this year, spurred by a growing understanding of tumors’ molecular bases and immunotherapy techniques, according to a new report that projects pharma and biotech trends for 2015. Read More
Drugmakers could end up paying millions of dollars on collection and disposal programs for unwanted drugs nationwide if industry groups aren’t able to stop a California county ordinance. Read More